Skip to NavigationSkip to content

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

Published on 28/07/16 at 08:51am

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime GLP-1 receptor agonist injection. It is indicated as an adjunct to diet and exercise for the treatment of adults with tyoe-2 diabetes.

Already approved in most EU countries, Japan, Brazil and India, among others, Adylxin has been launched as Lyxumia in many regions. It was in-licensed by Sanofi from Denmark-based Zealand Pharma.

The FDA’s approval is based on results from GetGoal clinical program and the ELIXA trial, which helped to confirm cardiovascular safety, as requested by the FDA. The GetGoal program features 13 clinical trials involving more than 5,000 adults. Each trial met the primary efficacy endpoint of blood glucose levels, or HbA1c, reduction.

Peter Guenter, executive VP of global diabetes and cardiovascular business unit at Sanofi, says: “Thje approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose targets. We are pleased with this approval, as it offers us the opportunity to continue helping patients treated with basal insulin who remain uncontrolled.”

The approval has triggered a milestone payment of $5 million to Zealand. The company are eligible to receive remaining milestone payments of up to $135 million as well as royalties on global sales.

CEO Britt Meelby Jensen, comments: “Today is an important day for Zealand. With the FDA approval of Adlyxin we have successfully passed the final regulatory milestone for the first Zealand invented product to become available for diabetes patients in the significant US market. We look forward to Sanofi’s launch of Adlyxin, while awaiting the FDA’s regulatory decision on iGlarLixi, the single product combination of Adlyxin and Lantus, expected in August 2016.”

Sean Murray

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches